JNJ-1761981 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to find the best dose of JNJ-1761981, a new cancer treatment, by testing how much can be safely and effectively injected directly into tumors. In the first part, researchers will determine a safe dose, while the second part focuses on finding the right amount to target tumor lesions. This trial might suit individuals with advanced or metastatic solid tumors who have not found success with standard treatments. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive it.
Is there any evidence suggesting that JNJ-1761981 is likely to be safe for humans?
Research on JNJ-1761981 remains in the early stages. Recent studies aim to find a dose that is safe and well-tolerated when administered directly into tumors. As these studies are just beginning, detailed information on side effects is limited. However, early trials typically focus on safety, so researchers will closely monitor and report any serious side effects.
In early trials, treatments often start with small doses. This approach allows researchers to observe the body's reactions and adjust the dosage if necessary. It is important to note that this treatment is not yet approved for general use. By participating in a trial, participants contribute to crucial research on its safety and effectiveness.12345Why do researchers think this study treatment might be promising for cancer?
Researchers are excited about JNJ-1761981 because it offers a new approach to treating cancer by being administered directly into tumors, which could lead to more targeted effects. Unlike traditional chemotherapy that circulates throughout the body, this intratumoral delivery method aims to concentrate the treatment where it's needed most, potentially minimizing side effects. Additionally, there is an option for some patients to receive cetrelimab, a systemic therapy, which could enhance the overall effectiveness of the treatment. This combination of localized delivery and optional systemic therapy is what makes JNJ-1761981 stand out.
What evidence suggests that JNJ-1761981 might be an effective treatment for cancer?
Research on JNJ-1761981 remains in the early stages, so limited information exists about its effectiveness in treating cancer. In this trial, participants will receive JNJ-1761981 directly into tumors to target cancer cells more precisely. The goal is to shrink tumors or slow their growth. Although human studies have not yet provided much data, researchers find this treatment promising due to its potential direct impact on tumors. Early studies, including this trial, focus on identifying a dose that is both safe and effective. Further research is necessary to determine its efficacy against cancer.16789
Who Is on the Research Team?
Johnson & Johnson Enterprise Innovation, Inc Clinical Trial
Principal Investigator
Johnson & Johnson Enterprise Innovation Inc.
Are You a Good Fit for This Trial?
This trial is for adults with advanced or metastatic solid tumors (except brain tumors) who have tried standard treatments without success, can't tolerate them, or have no other options. Participants must be in good physical condition and use effective birth control during and after the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants will receive JNJ-1761981 intratumorally to determine a safe and tolerable total dose
Dose Expansion
Participants in Cohort A will receive JNJ-1761981 at specified volumetric doses, with optional systemic therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- JNJ-1761981
Trial Overview
The study is testing different doses of a new drug called JNJ-1761981 injected directly into tumors. Some participants may also receive cetrelimab. The goal is to find safe and effective dose levels for treating solid tumors.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants in Cohort A will receive JNJ-1761981 at specified volumetric doses. Participants who receive more than 1 dose of JNJ-1761981 may receive optional systemic therapy with cetrelimab at the discretion of the treating physician.
Participants will receive JNJ-1761981 intratumorally to determine a safe and tolerable total JNJ-1761981 dose.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johnson & Johnson Enterprise Innovation Inc.
Lead Sponsor
Citations
A Study of JNJ-1761981 in Participants With Solid Tumors
The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981.
A Study of JNJ-1761981 in Participants With Solid Tumors
Trial overview: A Study of JNJ-1761981 in Participants With Solid Tumors.
A Study of JNJ-1761981 in Participants With Solid Tumors
The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981.
Better together: New combination therapy improves ...
For those patients who had failed two or more prior treatments, high-dose JNJ-4804 showed improved outcomes compared with golimumab and similar ...
Johnson & Johnson is transforming solid tumor cancer ...
Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society ...
Find a trial - J&J Clinical Trials
Find clinical trials that may match your needs. Search by condition, location, age, and more.
cetrelimab (JNJ-63723283) / J&J, Xoma
Clinical • IO biomarker • P2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CD8 • FOXP3.
Results of Novel Clinical Study of Guselkumab and ...
The rate of clinical remission was 47.9 percent in patients who received combination induction therapy with guselkumab and golimumab compared with either ...
Cetrelimab and JNJ-87704916 in Neoplasms - ICH GCP
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.